Citations

Clear

1434 citation(s) found for "Le, Nathan".

Adamantinomatous craniopharyngioma: outcomes from a US multicenter registry cohort (RAPID consortium study)
Celda, María Peris, Little, Andrew S, Gardner, Paul, Zenonos, Georgios, Evans, J., Fernandez-Miranda, Juan, Mamelak, Adam N, Rennert, Robert C, Couldwell, William T, Zada, Gabriel, Kim, Albert H, Silverstein, Julie M, Kim, Won, Bergsneider, Marvin, Wu, Kyle C, Prevedello, Daniel M, Zwagerman, Nathan, Cheok, Stephanie , Catalino, Michael P, Kshettry, Varun R, Karsy, Michael, Gompel, Jamie J Van, Karsy, Michael , Shinya, Yuki , Palit, Sandhya R. , Peris Celda, Maria, Karsy, Michael , Little, Andrew S. , Little, A.S., Pacult, Mark A. , Gardner, P., Zenonos, G., Evans, J., Fernandez-Miranda, J., Rennert, R.C., Couldwell, WilliamT., Zada, G., Kim, A.H., J.M., Silverstein, Kim, W., Bergsneider, M., Wu, K.C., Prevedello, D.M., Zwagerman, Nathan T. , Cheok, S., Catalino, Michael P. , Kshettry, Varun R. , Van, Gompel J.J.

Mayo Clinic

Journal of Neurosurgery | May 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.3171/2025.12.jns252065 | PMID 42066361 Get It

OBJECTIVE Adamantinomatous craniopharyngioma (ACP) is a rare type of brain tumor that affects a wide age range, from children to older adults. Due to the rarity of the disease, existing studies are predominantly limited to single-center or single-surgeon experiences, often lacking statistical power and generalizability. The aim of this study was to address this gap by providing a comprehensive analysis of ACP outcomes based on a large multicenter cohort from the Registry of Adenomas of the Pituitary and Related Disorders (RAPID). METHODS This multicenter retrospective cohort study was conducted via the RAPID consortium and assessed patients with histologically confirmed ACP treated surgically between August 2000 and November 2024 at high-volume pituitary centers across the United States. RESULTS Among the 359 patients (206 male, median age at primary surgery of 47 years) included in the analysis, 76% underwent endoscopic transsphenoidal surgery and 22% underwent craniotomy. Gross-total resection was achieved in 45% and subtotal resection in 47%. Notably, 120 of 311 patients (39%) presented with preoperative hypothalamic-pituitary axis dysfunction. Following all treatments, permanent hypothyroidism was reported in 40% of patients, adrenal insufficiency in 33%, and arginine vasopressin deficiency in 19%. Of 263 patients who underwent primary surgery, radiation therapy was administered in 84 (32%). Progression-free survival (PFS) declined from 66% at 1 year to 31% at 6 years. In the multivariable analysis, independent predictors of worse PFS included subtotal resection (HR 0.22, 95% CI 0.11–0.42; p = 0.001), partial resection (HR 0.11, 95% CI 0.04–0.28, p = 0.001), larger tumor size (HR 0.77, 95% CI 0.64–0.94; p = 0.009), and tumor extension beyond the sella and suprasellar regions (HR 0.21, 95% CI 0.06–0.74; p = 0.016). Primary surgery and salvage surgery groups showed comparable PFS. CONCLUSIONS In this large multicenter cohort study, gross-total resection was achieved in fewer than half of patients and was independently associated with improved PFS. Approximately one-third of patients underwent radiation therapy after primary surgery. These findings provide robust evidence supporting the prognostic value of extent of resection and inform contemporary treatment algorithms for ACP. The high incidence of postoperative endocrinopathy underscores the need for individualized multidisciplinary long-term care. While the retrospective design is a limitation, the multicenter approach enhances the generalizability of these results.
A complete human pancreatic cancer genome
Wagner, Justin , Keskus, Ayse G. , Oshima, Keisuke K. , Ranallo-Benavidez, T. Rhyker , McDaniel, Jennifer , Šikić, Mile , Lin, Dehui , Paulin, Luis F. , Sedlazeck, Fritz J. , Munding, Elizabeth M., Sanborn, JZ, Carroll, Andrew, Hassaine, Rayan, Cameron, Daniel, Catreux, Severine , Lee, Yeonghun , Murray, Lisa , Truong, Sean , Zimin, Aleksey V. , Cross, Erin , McGowan, Matthew , Vernich, Michael, Liss, Andrew S., Kocher, Jean-Pierre, Stephens, Zachary, Ahmad, Tanveer, Bryant, Asher , Dwarshuis, Nathan , Thibaud-Nissen, Francoise, Antipov, Dmitry, Koren, Sergey, Phillippy, Adam, Jain, Miten , Wenger, Aaron M. , Eacker, Stephen, Sahraeian, Sayed Mohammad Ebrahim, Boutros, Paul C., Patel, Yash, McConnell, Joseph , Borchers, Matthew , Gerton, Jennifer L. , Kostos, Paxton, Benjamin, Hila, Mootor, Mohammed Faizal Eeman , Xu, Yuan , Asri, Mobin , Miga, Karen H. , Park, Jimin , Paten, Benedict , Choi, Jae Young , Nguyen, L. , Robinson, Dan R. , Vo, Josh N. , Murtaza, Ghulam , Mason, Christopher E. , Cheng, Haoyu, Xiao, Chunlin , English, Adam C , Sedlazeck, Fritz J , Sanborn, J Zachary , Carroll, Andrew , Chang, Pi-Chuan , Cook, Daniel E , Shafin, Kishwar , de Ligt, Joep , Cameron, Daniel , Catreux, Severine , Lee, Yeonghun , Murray, Lisa , Truong, Sean , Brueffer, Christian , Cross, Erin , McGowan, Matthew , Vernich, Michael , Liss, Andrew S , Kocher, Jean-Pierre A , Stephens, Zachary , He, Hua-Jun , He, Zhiyong , Olson, Nathan D , Narzisi, Giuseppe , Jain, Miten , Wenger, Aaron M , Boutros, Paul C , Patel, Yash , Yamaguchi, Takafumi N , McConnell, Joseph , Gerton, Jennifer L , Guarracino, Andrea , Jehangir, Maryam , Mootor, Mohammed Faizal Eeman , Xu, Yuan , Miga, Karen H , Park, Jimin , Paten, Benedict , Luo, Ruibang , Zheng, Zhenxian , Choi, Jae Young , Nguyen, Linh , Vats, Pankaj , Gao, Shenghan , Murtaza, Ghulam , Mason, Christopher E , Barthel, Floris P , Xiao, Chunlin , Logsdon, Glennis A , Kolmogorov, Mikhail , Zook, Justin M , Keskus, Ayse , Ranallo-Benavidez, T Rhyker , Paulin, Luis F. , Sanborn, John Z., Ahmad, Tanveer, Thibaud‐Nissen, Françoise , Antipov, Dmitry , Koren, Sergey , Phillippy, Adam M. , Musunuri, Rajeeva , Eacker, Stephen M. , Yamaguchi, Takafumi N. , Jehangir, Maryam , Benjamin, Hila

Mayo Clinic

No container title available | May 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.01.722316 | PMID 42146349 Get It

Summary Cancer genome sequencing is essential for understanding tumor evolution and advancing precision medicine. 1 However, reference gaps and germline variants obscure detection of small and large somatic variants and methylation in repetitive regions. 1–3 It is common for tumor cells to gain or lose chromosome arms due to somatic structural changes that occur inside highly repetitive satellite DNA sequences in the centromeres. 4 To identify the full spectrum of somatic variants, including complex rearrangements, we construct and curate near-complete, haplotype-resolved assemblies of the most recent common ancestor of an early-passage broadly-consented hypodiploid pancreatic cancer cell line and matched normal tissues. The tumor assembly completely recapitulates all 35 tumor chromosomes observed with karyotyping, with multiple translocation-induced hybrid chromosomes. The hybrid chromosomes contain putative functional dicentric and fused centromeres, nested foldback inversions causing 14 breakpoints with a haplotype switch in a single event, and centromeric satellite tandem duplications up to 136 kbp. Direct comparison of tumor and normal assembly haplotypes uncovers >7,000 variants altering >1 Mbp of sequence in repetitive regions that have been hidden by reference gaps and germline variants. 44 % of somatic small variants change representation because they alter germline variants on GRCh38, impacting mutational signatures and kataegis/omikli clusters. Most somatic LINE insertions originate from two hypomethylated non-reference germline LINE insertions, highlighting their impact on insertion mutation burden. These assemblies demonstrate that centromeric, acrocentric, and telomeric regions conventionally excluded from analysis harbor extensive somatic and epigenetic changes. Resolving complete tumor genomes enables a deeper understanding of cancer structural plasticity and the endpoints of breakage-fusion-bridge cycles. These assembled, curated paired normal-tumor benchmarks will serve as a critical foundation for developing future algorithms to characterize the most intractable regions of cancer genomes.
A framework for quantifying and leveraging uncertainty in pre-trained CT denoising model
Gong, Hao, Huber, Nathan R., Kharat, Shravani A., Koo, Chi Wan , Yu, Lifeng, Leng, Shuai, Hsieh, Scott S., McCollough, Cynthia H., Gong, Hao , Huber, Nathan R. , Kharat, Shravani, Fletcher, Joel G. , Yu, Lifeng , Leng, Shuai , Hsieh, Scott S. , McCollough, Cynthia H.

Mayo Clinic

IEEE Transactions on Biomedical Engineering | May 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-12

10.1109/tbme.2026.3690022 | PMID 42085391 Get It

Biological markers of aging across the menopause transition: current evidence
Castaneda, Regina , Uddenberg, Erin R, Andrade, Maria D. Hurtado, Meek, Jesse L., Frankhouser, Kaylin N., Faubion, Stephanie S., Chini, Eduardo N., Brar, Pamila K., Shufelt, Chrisandra , Hurtado Andrade, Maria D, Shufelt, Chrisandra L , Castaneda, Regina , Faubion, Stephanie S. , Chini, Eduardo N. , LeBrasseur, Nathan K. , Brar, Pamila

Mayo Clinic

Menopause | May 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/gme.0000000000002802 | PMID 42084956 Get It

Importance and Objective: Aging is a complex biological process uniquely shaped in women by hormonal transitions, particularly across the menopause transition. While chronological age alone fails to capture individual health variability, emerging molecular biomarkers offer tools to quantify biological aging and understand mechanisms underlying age-related decline. This review synthesizes the current landscape of aging biomarkers, including senescence-associated secretory phenotype factors, epigenetic clocks, clonal hematopoiesis of indeterminate potential, and telomere length, with a particular emphasis on their relevance to menopause. Methods: This narrative review synthesizes human studies, translational research, and foundational basic science identified through PubMed searches through June 2025, examining aging biomarkers in general populations, among women in the menopause transition, and in relation to vasomotor symptoms and hormone therapy. Discussion and Conclusion: Evidence demonstrates that changes in biological aging biomarkers are observed across multiple molecular systems during midlife, including the menopause transition, reflecting broader age-related biological remodeling. Postmenopausal status, particularly following early or surgical menopause, has been associated with biological aging phenotypes, including elevated senescence-associated secretory phenotype factors, epigenetic age acceleration, clonal hematopoiesis, and shorter leukocyte telomere length, likely reflecting a combination of chronological aging, hormonal changes, and individual biological vulnerability. While severe vasomotor symptoms have been linked to higher epigenetic age, hormone therapy may favorably influence certain senescence markers and biological age discrepancy. Despite these advances, significant limitations constrain clinical translation, as current biomarkers capture overlapping biological processes and lack validated thresholds to define biological aging, especially in women. Future research requires large, longitudinal studies across diverse populations to establish clinically meaningful thresholds and sex-specific calibration. Advancing precision health strategies for women requires a better understanding of how reproductive and hormonal factors modify biomarker trajectories to improve risk prediction and to facilitate the development of targeted interventions for age-related diseases.
Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
González-Pons, María , Domínguez, Ricardo L. , Montalvan-Sanchez, Eleazar E. , Foster, Nathan R. , Strand, Carrie , Hernandez-Marrero, Jessica, Norwood, Dalton A. , McMurray, Ryan P. , Roman, Keila L. Rivera , Centeno-Girona, Hilmaris , Ghandour, Fatme , Diffalha, Sameer Al, Samadder, N. Jewel , Rodriguez, Luz M. , Morgan, Douglas R. , Cruz-Correa, Marcia, Hernández, Jessica , González‐Pons, María , Strand, Carrie A , Hernandez-Marrero, Jessica , Rivera Roman, Keila L , Rodriguez-Murillo, Aida , Ghandour, Fatme , Al Diffalha, Sameer , Samadder, N Jewel , Umar, Asad , Richmond, Ellen S. , RODRIGUEZ, LUZ MARIA , Limburg, Paul J , Morgan, Douglas R , Cruz-Correa, Marcia , McMurray, Ryan P , Domínguez, Ricardo L. , Montalvan-Sanchez, Eleazar Enrique. , Norwood, Dalton Argean , Centeno‐Girona, Hilmaris , Limburg, Paul J. , Cruz‐Correa, Marcia

Mayo Clinic

Cancer Prevention Research | May 4, 2026 | Volume: 19 | Issue: 7 | Pages: 403-413

10.1158/1940-6207.capr-25-0363 | PMID 42077070 Get It

Abstract Globally, gastric adenocarcinoma is the fourth leading cause of cancer mortality and a major cancer disparity in the United States. Chemoprevention strategies are lacking for high-risk individuals with gastric premalignant conditions (GPMC). Curcumin, the principal curcuminoid in turmeric, exerts immunomodulatory effects in the epithelium and against Helicobacter pylori, and studies suggest chemoprevention potential. We conducted a double-blind, phase IIa randomized controlled trial in high-risk populations in Puerto Rico and Honduras. We investigated the utility of a bioavailable formulation of curcumin (Meriva) among individuals with H. pylori–negative GPMC, specifically, multifocal atrophic gastritis (MAG) or gastric intestinal metaplasia (GIM). Patients were 1:1 randomized to 1,000 mg Meriva daily or placebo for a 6-month intervention with endoscopy at baseline and 6 months. Outcomes included assessment of epithelial cytokine and chemokine levels, histology, and DNA damage as assessed by γ-H2AX phosphorylation IHC. Of the 110 subjects screened, 50 participants were randomized, and 48 completed the trial. A significant reduction in gastric mucosal IL1β levels from baseline in the gastric body, the primary endpoint, was observed in the Meriva group (P = 0.032). Changes in epithelial IL8, TNFα, and inducible protein 10 levels and gastric mucosal histology and DNA damage (secondary endpoints) were similar between arms. Curcumin (Meriva) was safe, well-tolerated, and showed potential as a curcuminoid chemoprevention agent in H. pylori–negative patients with GPMC. A potential reduction in gastric inflammation as measured by gastric mucosal IL1β levels was observed. Further studies are warranted, including studies in H. pylori–positive individuals, based upon the curcuminoid direct effects on H. pylori. Prevention Relevance: Gastric adenocarcinoma is a leading cause of cancer mortality worldwide. Chemoprevention candidates for GPMCs are limited. This randomized phase IIa trial evaluated a bioavailable curcumin formulation in high-risk individuals with MAG and GIM. The results support further study of curcuminoids for gastric cancer risk reduction. See related Spotlight, p. 387 See related article by Morgan et al., p. 391
In situ impedance analysis device for clot characterization in large vessel occlusion acute ischemic stroke, a first-in-human study
Cheung, Andrew , Rice, Henry, Villiers, Laetitia de , Manning, Nathan , Saleme, Suzana, Forestier, Géraud , Lafaurie-Janvore, Julie, Rambeau, Joachim, Bozsak, Franz, Kadirvel, Ramanathan , Doyle, Karen, Brinjikji, Waleed, Liebeskind, David S. , Cordato, Dennis, de Villiers, Laetitia , Manning, Nathan W , Forestier, Géraud , Rambeau, Joachim , Kadirvel, Ram , Liebeskind, David S. , Rouchaud, Aymeric , Cordato, Dennis , Rice, Henry, Saleme, Suzana , Nascimento, Vinicius Carraro do , Doyle, Karen , Brinjikji, Waleed , Rouchaud, Aymeric

Mayo Clinic

Journal of NeuroInterventional Surgery | May 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: jnis-2025-024772

10.1136/jnis-2025-024772 | PMID 42070796 Get It

Background Large vessel occlusion (LVO) stroke is associated with a high risk of permanent disability. There are no reliable tools providing periprocedural information on clot characteristics, such as composition and length, that may impact first pass effect, which has been shown to improve functional outcomes. In the first study of a novel technology, we evaluated whether the Clotild Smart Guidewire System (Clotild), an impedance-based device, can provide in situ information on clot characteristics during a mechanical thrombectomy procedure. Methods This is the first-in-human, international, multicentric, single-arm trial involving LVO stroke patients. Of 45 enrolled subjects, 41 constituted the safety population; 39 was the per protocol population, of which 26 subjects with complete impedance data comprised the performance population. The latter was divided into development (11 subjects) and validation (15 subjects) populations for prediction model development and assessment. The safety endpoint assessed Clotild-related intracranial vessel perforation/dissection. Performance endpoints evaluated Clotild’s ability to perform classification of impedance measurements distinguishing substantial versus negligible local content in red blood cells (RBCs) and platelets, to detect the arterial wall and the distal end of the clot. Results The safety endpoint was met in all subjects. Performance analysis comparing the agreement between Clotild’s output and impedance experts’ readings showed an area under the receiver operating characteristic curve (AUC) of 0.97 (95% CI 0.93 to 0.99) for RBC, and 0.94 (95% CI 0.89 to 0.98) for platelet clot composition. Regarding detection, Clotild’s performance showed an AUC of 0.69 (95% CI 0.59 to 0.77) for the arterial wall, and 0.83 (95% CI 0.59 to 1.00) for the distal end of the clot. Conclusions Clotild was proven safe to acquire impedance data and to provide information on in situ clot characteristics in large vessel occlusions.
Abstract TU205: The Effect of Physical Activity on the Gut Microbiome in Prediabetes: Results from a Randomized Controlled Trial
Demmer, Ryan, Pope, Zachary, Avenido, Francis Ryan, Mitchell, Nathan, Hubbard, Paige Richmond, Johnson, Stephen, McDonough, DJ, Rydell, Sarah, Johnson, Abigail, Pereira, Mark, Demmer, Ryan T. , Pope, Zachary , Mitchell, Nathan R , Hubbard, Paige F. Richmond, Johnson, Stephen, Sharma, Shweta , Rydell, Sarah A.

Mayo Clinic

Circulation | April 30, 2026 | Volume: 153 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.153.suppl_1.tu205 Get It

Objective: To test the effect of physical activity on the gut microbiome and circulating short chain fatty acids among sedentary overweight/obese adults with prediabetes. We hypothesized that randomization to increased physical activity would result in gut microbiome changes. Methods: \We randomized 77 adults with prediabetes and a sedentary lifestyle into one of two groups: 1) Intervention Group: Invited to engage in home-based moderate intensity walking 3x/week for 30 minutes/session in weeks 1-4 and for 45 minutes/session during weeks 5-8 of the 8-week intervention; or 2) Control Group: Maintained habitual physical activity levels. We performed metagenomic sequencing from stool collected at baseline, week 4, and week 8, with short-chain fatty acids (SCFA) measured from serum collected at baseline and week 8. Taxonomic and functional profiling were performed on the metagenomic reads; alpha diversity metrics were subsequently derived. Linear regression assessed the difference in change between the intervention and control groups for alpha-diversity and SCFA levels. Results: We screened 1,533 participants for eligibility and consented 132. Of these, 87 entered the run-in phase and 77 were randomized. Participants were 51.4±8.9 years old, 87.7% female, and 74% non-Hispanic White. Mean fasting glucose was 103.3±13.2 while mean BMI was 34.4±5.7. In comparison to the control group, the intervention group experienced decreased alpha diversity as characterized by Shannon, Richness, and Faith’s diversity indices by week 8 of the intervention (P<0.05). SCFA levels trended towards improvement in the intervention group, but the results were not statistically significant. Functional analysis of KEGG ontologies revealed themes consistent with a microbiome with enhanced metabolic activity and host-relevant metabolic signaling (Figure). Conclusions: Randomization to a walking intervention resulted in modest gut microbiome changes among adults with overweight/obesity and prediabetes.
Strengthening Health Research to Advance Equitable, Patient-Centered Care
Rutten, Lila J. Finney, Delafield, Nathan L., Mangold, Aaron R., Bold, Richard J. , Rutten, Lila J. Finney , Delafield, Nathan L. , Mangold, Aaron R.

Mayo Clinic

NEJM Catalyst | April 30, 2026 | Volume: 7 | Issue: s2 | Pages: No page available

10.1056/cat.26.0132 | PMID 42455986 Get It

Characterizing circadian rest–activity rhythm patterns across Alzheimer's disease continuum in Down syndrome
Giménez, Sandra , Vaqué-Alcázar, Lídia, Clos, Susana, Benejam, Bessy, Carmona-Iragui, Maria, Maure‐Blesa, Lucía, Videla, Laura, Zhu, Nuole , Altuna, Miren, Arranz, Javier, Barroeta, Isabel , Rodríguez-Baz, Íñigo, Bueno, Ana, Fernandez, Susana, Pertierra, Lucía , Alcolea, Daniel, Miller, Bruce, Ruiz, Joaquin, Wu, Hau-Tieng, Lleó, Alberto, Osorio, Ricardo S, Blessing, Esther M, Fortea, Juan, Vaqué‐Alcázar, Lídia , Clos, S. , Benejam, Bessy , Carmona‐Iragui, María , Videla, Laura , Altuna, Miren , Arranz, Javier , Rodríguez‐Baz, Íñigo , Bejanin, Alexandre , Fernández, Susana , Soriano, Laura del Hoyo , Alcolea, Daniel , Miller, Bruce L , Grinberg, Lea T. , Lisgaras, Christos Panagiotis , Lleó, Alberto , Osorio, Ricardo S. , Fortea, Juan

Mayo Clinic

Alzheimer's & Dementia | April 30, 2026 | Volume: 22 | Issue: 5 | Pages: No page available

10.1002/alz.71409 | PMID 42056071 Get It

Abstract INTRODUCTION Sleep and circadian rest–activity rhythm (RAR) disruption may bidirectionally relate to Alzheimer's disease (AD). Down syndrome (DS), the most common genetic cause of AD, presents sleep disorders, yet RAR patterns across the DS‐associated AD continuum remain uncharacterized. METHODS We analyzed 7‐day wrist actigraphy in 140 adults with DS (108 asymptomatic; 32 AD dementia) and 41 unimpaired controls. General linear models, adjusted for age, sex, sleep efficiency, and obstructive sleep apnea (OSA) severity, tested group differences, with interaction terms included to evaluate group‐specific associations. RESULTS DS showed lower relative amplitude and higher nocturnal activity, already in asymptomatic individuals. Rhythm strength declined further with AD progression, while regularity and phase timing remained preserved until dementia. Findings were independent of sleep duration and OSA. DISCUSSION Adults with DS showed early RAR disturbance that progressed across the AD continuum, paralleling sporadic AD. Circadian RAR features may be scalable biomarkers of AD progression.